Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (191-200 of 484) with videos related to

Pageof 49
Sort By:
American Journal of Men'S Health|April 18, 2017
Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk DisparitiesDorothy Long Parma, Edgar Muñoz, Susan M Ogden, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 9, 2022
Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention TrialJeannette M Schenk, Cathee Till, Marian L Neuhouser, et al.
Journal of Community Medicine & Health Education|August 26, 2014
The Development of a Minority Recruitment Plan for Cancer Clinical TrialsMonica Trevino, Susan Padalecki, Anand Karnad, et al.
Cancer|March 2, 2005
Estimated impact of the Prostate Cancer Prevention Trial on population mortalityJoseph M Unger, Ian M Thompson, Michael LeBlanc, et al.
The Journal of Urology|July 12, 2005
The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trialJavier Hernáandez, Samira Syed, Geoffrey Weiss, et al.
The Prostate|May 29, 2009
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention TrialJeannette M Schenk, Alan R Kristal, Marian L Neuhouser, et al.
The Journal of Urology|August 12, 2005
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trialRuth D Etzioni, Nadia Howlader, Pamela A Shaw, et al.
American Journal of Epidemiology|July 2, 2013
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Jeannette M Schenk, Rachel Hunter-Merrill, Yingye Zheng, et al.
American Journal of Epidemiology|February 12, 2008
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Kathryn B Arnold, Jeannette M Schenk, et al.
Medical Hypotheses|August 6, 2018
mTOR inhibitors for treatment of low-risk prostate cancerMichael A Liss, Lanette Rickborn, John DiGiovanni, et al.
Pageof 49

Showing results (191-200 of 484) with videos related to

Sort By:
Pageof 49
American Journal of Men'S Health|April 18, 2017
Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk DisparitiesDorothy Long Parma, Edgar Muñoz, Susan M Ogden, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 9, 2022
Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention TrialJeannette M Schenk, Cathee Till, Marian L Neuhouser, et al.
Journal of Community Medicine & Health Education|August 26, 2014
The Development of a Minority Recruitment Plan for Cancer Clinical TrialsMonica Trevino, Susan Padalecki, Anand Karnad, et al.
Cancer|March 2, 2005
Estimated impact of the Prostate Cancer Prevention Trial on population mortalityJoseph M Unger, Ian M Thompson, Michael LeBlanc, et al.
The Journal of Urology|July 12, 2005
The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trialJavier Hernáandez, Samira Syed, Geoffrey Weiss, et al.
The Prostate|May 29, 2009
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention TrialJeannette M Schenk, Alan R Kristal, Marian L Neuhouser, et al.
The Journal of Urology|August 12, 2005
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trialRuth D Etzioni, Nadia Howlader, Pamela A Shaw, et al.
American Journal of Epidemiology|July 2, 2013
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Jeannette M Schenk, Rachel Hunter-Merrill, Yingye Zheng, et al.
American Journal of Epidemiology|February 12, 2008
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Kathryn B Arnold, Jeannette M Schenk, et al.
Medical Hypotheses|August 6, 2018
mTOR inhibitors for treatment of low-risk prostate cancerMichael A Liss, Lanette Rickborn, John DiGiovanni, et al.
Pageof 49